Efficacy of risdiplam in spinal muscular atrophy: A systematic review and meta‐analysis

• Published in: Pharmacotherapy 2024-01, Vol.44 (1), p.97-105
• Main Authors: Pascual‐Morena, Carlos, Martínez‐Vizcaíno, Vicente, Cavero‐Redondo, Iván, Martínez‐García, Irene, Moreno‐Herráiz, Nerea, Álvarez‐Bueno, Celia, Saz‐Lara, Alicia
• Format: Article
• Language: English
• Subjects: Adverse events; Azo Compounds; Child; Humans; Infant; Meta-analysis; motor neuron disease; Muscular Atrophy, Spinal - drug therapy; Neuromuscular diseases; Phenotypes; Pyrimidines; Respiratory function; Spinal Muscular Atrophies of Childhood - drug therapy; Spinal muscular atrophy; Systematic review
• ISSN: 0277-0008; 1875-9114
• DOI: 10.1002/phar.2866

This systematic review and meta‐analysis aimed to assess the efficacy and safety of risdiplam on motor and respiratory function in spinal muscular atrophy (SMA). We systematically searched Medline, Scopus, Web of Science, and the Cochrane Library from inception to March 2023. We included pre‐post studies that determined the effect of risdiplam on the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP‐INTEND), the 32‐item Motor Function Measure (MFM32), the Revised Upper Limb Module (RULM), the Hammersmith Functional Motor Scale – Expanded (HFMSE), respiratory function, and the proportion of risdiplam‐related adverse events in a population with SMA (phenotypes 1 and 2/3). Meta‐analyses were also performed where possible. Eleven studies were included. After 12 months of treatment, 57% of participants with SMA1 achieved a CHOP‐INTEND score ≥ 40 points, and more than half were able to feed orally and had head control. In SMA2/3, MFM32, RULM, and HFMSE increased by 2.09 (1.17, 3.01), 1.73 (1.25, 2.20), and 1.00 (0.40, 1.59) points, respectively. Efficacy on respiratory function in SMA2/3 was inconsistent. Finally, 16% of participants experienced adverse events, but serious adverse events could not be quantified due to a lack of cases. The limited available evidence suggests that risdiplam is an effective and safe drug for the treatment of SMA. In addition, long‐term clinical benefit may be partly determined by the stage of disease at which treatment is initiated.